Építés alatt – nem éles oldal
Belépés

Omega-3 fatty acids (fish oil) & Schizophrenia

Checked 2026. nov. 11. including AI · Schizophrenia

AI-generated image

Written based on 26 research studies on PubMed, searched on 2026. nov. 11..

The claim

Posts online say that omega-3 fatty acids (fish oil) helps with schizophrenia.

Where research stands

We found 99 published papers on omega-3 fatty acids (fish oil) and schizophrenia. They were published between 1981 and 2026. 25 of them are studies in people. 23 of them compared people who got it with a group that did not. 10 were studies in animals, and none was only in cells in the lab. 26 papers are reviews that sum up other studies. 1 new study in people is running or will start soon, say the trial registers.

  • 25In people23 with a comparison group
  • 10In animals
  • 0Only in the lab

What the studies found

We have not summed up these studies in words yet. The most important papers are listed under Sources.

Verdict

Omega-3 fatty acids (fish oil) has been tested in randomised trials in people with schizophrenia.

What this means for you: A study in people is not proof that it helps you. Do not stop or change your medicines because of it. Ask your doctor before you start taking it.

Sources

  1. Omega-3 fatty acids reduce cardiometabolic risk in first-episode schizophrenia patients treated with antipsychotics: Findings from the OFFER randomized controlled study.2021 · Schizophr Res · Randomised trial
  2. No Impact of Omega-3 Fatty Acid Supplementation on Symptoms or Hostility Among Patients With Schizophrenia.2020 · Front Psychiatry · Randomised trial
  3. Omega-3 fatty acids ameliorate cognitive dysfunction in schizophrenia patients with metabolic syndrome.2020 · Brain Behav Immun · Randomised trial
  4. Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial.2019 · Psychopharmacology (Berl) · Randomised trial
  5. A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.2019 · Schizophr Res · Randomised trial
  6. Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate.2018 · Psychiatry Res · Randomised trial
  7. Omega-3 fatty acid supplementation may prevent loss of gray matter thickness in the left parieto-occipital cortex in first episode schizophrenia: A secondary outcome analysis of the OFFER randomized controlled study.2018 · Schizophr Res · Randomised trial
  8. Neurocognitive effects of an omega-3 fatty acid and vitamins E+C in schizophrenia: A randomised controlled trial.2018 · Prostaglandins Leukot Essent Fatty Acids · Randomised trial
  9. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol.2017 · Trials · Study in people
  10. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.2017 · Early Interv Psychiatry · Study in people
  11. Omega-3 Polyunsaturated Fatty Acids as Adjunctive Therapy to Antipsychotic Treatment in Adults with Schizophrenia: A Systematic Review and Meta-Analysis.2026 · Brain Sci · Review
  12. The therapeutic effect of omega-3 polyunsaturated fatty acids on symptom severity of psychosis: A systematic review and meta-analysis.2024 · Eur Psychiatry · Review
  13. A Systematic Review of Effectiveness of Omega-3 Fatty Acid Supplementation on Symptoms, Social Functions, and Neurobiological Variables in Schizophrenia.2021 · Biol Res Nurs · Review
  14. Shared Biological Pathways between Antipsychotics and Omega-3 Fatty Acids: A Key Feature for Schizophrenia Preventive Treatment?2021 · Int J Mol Sci · Review
  15. Effects of omega-3 polyunsaturated fatty acids supplements on psychopathology and metabolic parameters in schizophrenia: A meta-analysis of randomized controlled trials.2021 · J Psychopharmacol · Review
  16. Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms.2020 · Lipids Health Dis · Review
  17. Prenatal omega-3 fatty acids supplementation mitigates some schizophrenia-like deficits in offspring: A PET and MRI study in a rat model.2025 · Transl Psychiatry · In animals
  18. Supplement Treatment with NAC and Omega-3 Polyunsaturated Fatty Acids during Pregnancy Partially Prevents Schizophrenia-Related Outcomes in the Poly I:C Rat Model.2023 · Antioxidants (Basel) · In animals
  19. Omega-3 fatty acids during adolescence prevent schizophrenia-related behavioural deficits: Neurophysiological evidences from the prenatal viral infection with PolyI:C.2021 · Eur Neuropsychopharmacol · In animals
  20. Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia.2016 · Biomed Pharmacother · In animals
  21. Effects of omega-3 supplementation on interleukin and neurotrophin levels in an animal model of schizophrenia.2015 · An Acad Bras Cienc · In animals
  22. Omega-3 fatty acids prevent the ketamine-induced increase in acetylcholinesterase activity in an animal model of schizophrenia.2015 · Life Sci · In animals
  23. Correlations between omega-3 fatty acids and inflammatory/glial abnormalities: the involvement of the membrane and neurotransmitter dysfunction in schizophrenia.2023 · Front Cell Neurosci · Other paper
  24. Higher stress response and altered quality of life in schizophrenia patients with low membrane levels of docosahexaenoic acid.2023 · Front Psychiatry · Other paper
  25. Determining nonesterified and total docosahexaenoic acid and eicosapenaenoic acid concentrations by LC-MS/MS in the plasma of patients with schizophrenia.2022 · Bioanalysis · Other paper
  26. Reduced Cerebrospinal Fluid Levels of Lysophosphatidic Acid Docosahexaenoic Acid in Patients With Major Depressive Disorder and Schizophrenia.2021 · Int J Neuropsychopharmacol · Other paper

More checked claims